Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California. Show more

3565 General Atomics Court, San Diego, CA, 92121, United States

https://www.contineum-tx.com

Biotechnology

Healthcare

Start AI Chat

Market Cap

502.2M

52 Wk Range

$3.35 - $16.33

Previous Close

$13.45

Open

$13.19

Volume

111,074

Day Range

$13.14 - $14.06

Enterprise Value

247.5M

Cash

262.9M

Avg Qtr Burn

-13.04M

Insider Ownership

1.03%

Institutional Own.

90.66%

Qtr Updated

12/31/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
PIPE-307 (M1 Receptor Inhibitor) Details Major Depressive Disorder (MDD)	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
PIPE-307 Details Relapsing-remitting multiple sclerosis (RRMS)	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
PIPE-791 Details Idiopathic pulmonary fibrosis (IPF)	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
PIPE-791 Details Osteoarthritis (OA) and low back pain (LBP)	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
PIPE-791 Details Neuroscience, Inflammation and Immunology (NI&I) Indications	Phase 1b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.